Silver Book Fact

According to the Pharmaceutical Research and Manufacturers of America, a medicine in development that is a monoclonal antibody, targets the epidermal growth factor receptor. Because cancer cells can become dependent on the growth signals that are mediated through the epidermal growth factor receptor, blocking it may stop the growth of cancer cells and eradicate existing cancer cells.

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Since the war on cancer was declared in 1971, our arsenal has tripled. New drugs accounted for around 50-60% of the increase in six-year cancer survival rates since 1975.…  
  • A modest 1% reduction in cancer mortality would be worth close to $500 billion. A cure for cancer (if one is feasible) would be worth around $50 trillion.  
  • Since 1980, 83 percent of gains in life expectancy for cancer patients have been attributable to new treatments.  
  • 5-Year Relative Survival Rates for Cancers in U.S.  
  • According to the Pharmaceutical Research and Manufacturers of America, a cancer medicine in development is designed to induce a powerful immune response to melanoma.